[{"address1": "399 Thornall Street", "address2": "First Floor", "city": "Edison", "state": "NJ", "zip": "08837", "country": "United States", "phone": "732 902 4000", "fax": "732 902 4100", "website": "https://hepionpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Mr. John Patrick Brancaccio CPA", "age": 75, "title": "Interim CEO, Interim CFO & Executive Chairman", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 81000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Sharen  Pyatetskaya", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.642, "open": 0.655, "dayLow": 0.631, "dayHigh": 0.655, "regularMarketPreviousClose": 0.642, "regularMarketOpen": 0.655, "regularMarketDayLow": 0.631, "regularMarketDayHigh": 0.655, "beta": 1.845, "forwardPE": -0.05664042, "volume": 9933, "regularMarketVolume": 9933, "averageVolume": 155473, "averageVolume10days": 18650, "averageDailyVolume10Day": 18650, "marketCap": 3754357, "fiftyTwoWeekLow": 0.553, "fiftyTwoWeekHigh": 5.31, "fiftyDayAverage": 0.7151, "twoHundredDayAverage": 1.59468, "currency": "USD", "enterpriseValue": 3488821, "floatShares": 5277205, "sharesOutstanding": 5799130, "sharesShort": 62608, "sharesShortPriorMonth": 81193, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0108, "heldPercentInsiders": 0.00102, "heldPercentInstitutions": 0.14526, "shortRatio": 2.35, "shortPercentOfFloat": 0.0108, "impliedSharesOutstanding": 5799130, "bookValue": 0.322, "priceToBook": 2.010559, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -28365592, "trailingEps": -6.41, "forwardEps": -11.43, "lastSplitFactor": "1:20", "lastSplitDate": 1683763200, "enterpriseToEbitda": -0.111, "52WeekChange": -0.8568584, "SandP52WeekChange": 0.34083736, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "HEPA", "underlyingSymbol": "HEPA", "shortName": "Hepion Pharmaceuticals, Inc.", "longName": "Hepion Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1392042600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bec39233-f713-3fce-8d16-915e909efc3e", "messageBoardId": "finmb_244424098", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6474, "targetHighPrice": 30.0, "targetLowPrice": 30.0, "targetMeanPrice": 30.0, "targetMedianPrice": 30.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2115047, "totalCashPerShare": 0.365, "ebitda": -31507800, "totalDebt": 154090, "quickRatio": 2.168, "currentRatio": 5.619, "debtToEquity": 4.326, "returnOnAssets": -0.92824, "returnOnEquity": -1.89515, "freeCashflow": -26445260, "operatingCashflow": -34783512, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]